– Business combination transaction with OTR Acquisition Corp., a special purpose acquisition company, completed – – Combined company Comera Life Sciences Holdings, Inc. will be listed on the Nasdaq Capital Market under ticker symbol "CMRA" – Comera Life Sciences Holdings, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the completion of its business combination with OTR Acquisition Corp. (NASDAQ:OTRAU, OTRA and OTRAW))) (referred herein as "OTR"), a publicly traded special purpose acquisition company (SPAC). Comera Life Sciences Holdings, Inc., the resulting comb

Comera Life Sciences, Inc. ("Comera" or the "Company"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced it has entered into a research collaboration with a top 10 global pharmaceutical company and developer of medicines across oncology, hematology and immunology and other therapeutic areas. Under the terms of the agreement, Comera will utilize its proprietary SQore™ formulation platform to develop a subcutaneous formulation of the partner's currently marketed medicine. "Our second announced collaboration this year is a critical milestone in our long-term strategy to partner with top-tier pharma c

Comera Life Sciences, Inc., which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that Robert P. Mahoney, Ph.D., Chief Scientific Officer, will present at the PEGS Boston Conference & Expo, being held May 2-6, 2022, in-person. Dr. Mahoney will discuss Comera's lead, patented caffeine-based excipient, which significantly reduced the viscosity of prominent monoclonal antibodies without affecting their stability or biologic activity in a recent peer-reviewed study.1 The presentation details are as follows: Title: Viscosity Reducing Excipients for Highly Concentrated Antibody Formulations Time: May 4, 202

Today, Comera Life Sciences, Inc. ("Comera" or the "Company") and Intas Pharmaceuticals Ltd. ("Intas") announced a research collaboration to develop a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220418005526/en/ Under the terms of the partnership agreement, Comera will develop a differentiated formulation of an Intas product using Comera's innovative proprietary SQore™ formulation platform. Intas will initially provide research funding with the option to acquire global rights to the formulation through an exclusive license w

Special meeting of OTR stockholders scheduled for May 10, 2022 Comera Life Sciences, Inc. ("Comera"), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, and OTR Acquisition Corp. (NASDAQ:OTRA) ("OTR"), a publicly traded special purpose acquisition company (SPAC), today announced that the Securities and Exchange Commission ("SEC") has declared the Registration Statement on Form S-4 filed in connection with the proposed business combination between the two companies, to be effective. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220418005109/en/ A special

Investor Call Rescheduled to Tuesday, Feb. 8 at 8:30 a.m. EST to Discuss Combination between Comera Life Sciences, Inc. and OTR Acquisition Corp. OTR Acquisition Corp. (NASDAQ:OTRAU, OTRA and OTRAW))), a publicly traded special purpose acquisition company (SPAC), today announced the confidential submission with the U.S. Securities and Exchange Commission ("SEC") of a draft registration statement on Form S-4 (the "Registration Statement") relating to its previously announced proposed business combination with Comera Life Sciences, Inc. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220203006027/en/ In addition, the investor call

Comera Life Sciences is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience This transaction is expected to enable further investment in a compassionate new era in medicine by applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms and thereby give patients greater flexibility in their care Combined company to have an implied initial equity value of approximately $258.4 million translating into an enterprise value of approximately $151.3 million, with the proposed business combination expected to provide approximately $107 million in g

4 - OTR Acquisition Corp. (0001821318) (Issuer)

4 - OTR Acquisition Corp. (0001821318) (Issuer)

4 - OTR Acquisition Corp. (0001821318) (Issuer)

4 - OTR Acquisition Corp. (0001821318) (Issuer)

4 - OTR Acquisition Corp. (0001821318) (Issuer)

4 - OTR Acquisition Corp. (0001821318) (Issuer)

4 - OTR Acquisition Corp. (0001821318) (Issuer)

4 - OTR Acquisition Corp. (0001821318) (Issuer)

4 - OTR Acquisition Corp. (0001821318) (Issuer)

4 - OTR Acquisition Corp. (0001821318) (Issuer)

SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

SC 13G - OTR Acquisition Corp. (0001821318) (Subject)

SC 13G - OTR Acquisition Corp. (0001821318) (Subject)

SC 13G - OTR Acquisition Corp. (0001821318) (Subject)

SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

SC 13G - OTR Acquisition Corp. (0001821318) (Subject)

SC 13G/A - OTR Acquisition Corp. (0001821318) (Subject)

SC 13G - OTR Acquisition Corp. (0001821318) (Subject)